Kalaris Therapeutics Inc (KLRS) Stock Analysis

What Kalaris Therapeutics Inc does

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

Key metrics

ETFs linked to KLRS

Broad-market and Healthcare sector ETFs an investor holding Kalaris Therapeutics Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KLRS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Kalaris Therapeutics Inc?

Kalaris Therapeutics Inc trades under the ticker KLRS on NASDAQ.

Which exchange is KLRS listed on?

KLRS is listed on NASDAQ.

What sector does Kalaris Therapeutics Inc operate in?

Kalaris Therapeutics Inc is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KLRS in a portfolio?

PortView shows KLRS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.